Ann: Zelira to Collaborate with the Parkinsons Foundation, page-24

The depth of the product line, with time lines approaching announcements, and a potentially huge distribution network, means there is lots of potential upside here.

But, its still a penny share. One not so good announcement can do a lot of damage, which will take time to repair.

On face value, we seem to be in a good spot. The April quaterly, if it shows good revenue could give us a huge rerate.

I am still really happy with the money i have parked in ZLD. I was also very happy when the new company constitution described how any dividends would be distributed. That is the future i really want to see here.

Everything considered, I think the Market cap at the moment is appropriate. But can see many multiple rerates with the announcements ahead if they come in to match or exceed market expectations.

I guess we will all know in the next few months. Real news flows should be the quarterly this week, Insomnia in Feb, and Pain and Quarterly in Apr. That should be able to keep our interest.

So hopefully great news for both patients and shareholders ahead.